http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2729100-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7337c7043b3fa2a52339f0fdbc07dd5b http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ec2cf2772a722c89d7cdeaf3f7f441cc |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-715 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-75 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-71 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5044 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2878 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate | 2012-01-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_51e4a60dbb022281987e424384527239 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e553d84d06b7c9210252f40cc61ee94 |
| publicationDate | 2019-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2729100-T3 |
| titleOfInvention | Use of at least one P75NTR receptor inhibitor, alone or in association with at least one TRKA receptor activator, or at least one trka receptor activator, for the treatment of chronic inflammatory diseases |
| abstract | Selected compound of p75NTR receptor inhibitors, alone or in association with at least one selected compound of TrkA receptor activators, or a selected compound of TrkA receptor activators, for use in the anti-inflammatory treatment of chronic inflammatory diseases of autoinflammatory or autoimmune origin , with the exclusion of diseases of allergic origin, in patients in whom the ratio of TrkA receptor / p75NTR receptor expression is less than 1 in inflamed tissues or cells of biological fluids; wherein p75NTR receptor inhibitors are selected from the group consisting of monospecific or bispecific polyclonal and monoclonal p75NTR receptor binding antibodies, chimeric molecules whose structure includes soluble p75NTR receptor, monomeric cyclic and dimeric compounds binding to the p75NTR receptor. and wherein TrkA receptor activators are selected from the group consisting of TrkA receptor binding polyclonal and monoclonal antibodies, compounds monomeric or dimeric cyclic NGF analogs, recombinant NGF or mutant recombinant NGF. |
| priorityDate | 2011-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 334.